Physical activity coaching in patients with interstitial lung diseases: A randomized controlled trial
Chronic Respiratory Disease · 2024-01 · 21
DOI: 10.1177/14799731241235231 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Chronic Respiratory Disease, online erschienen am 21.03.2024. Verfasst von Sofie Breuls und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Mentoring, Lung Diseases, Interstitial. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Galápagos, Boehringer Ingelheim, AstraZeneca Czech Republic.
Abstract (Originalsprache)
Objectives
Physical activity is reduced in patients with interstitial lung disease (ILD) and physical inactivity is related to poor health outcomes. We investigated the effect of a telecoaching intervention to improve physical activity in patients with ILD.
Methods
Eighty patients with ILD were randomized into the intervention or control group. Patients in the intervention group received a 12-week telecoaching program including a step counter, a patient-tailored smartphone application, and coaching calls. Patients in the control group received usual care. Physical activity (primary outcome), physical fitness and quality of life were measured at baseline and 12 weeks later with an accelerometer, 6-min walking test and quadriceps muscle force and the King’s Brief Interstitial Lung Disease questionnaire (K-BILD).
Results
Participation in telecoaching did not improve physical activity: between-group differences for step count: 386 ± 590 steps/day, p = .52; sedentary time: 4 ± 18 min/day, p = .81; movement intensity: 0.04 ± 0.05 m/s 2 , p = .45). Between-group differences for the 6-min walking test, quadriceps muscle force and K-BILD were 14 ± 10 m, p = .16; 2 ± 3% predicted, p = .61; 0.8 ± 1.7 points, p = .62 respectively.
Conclusions
Twelve weeks of telecoaching did not improve physical activity, physical fitness or quality of life in patients with ILD. Future physical or behavioural interventions are needed for these patients to improve physical activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium.
- Department of Physiotherapy, Faculty of Physical Culture, Palacký University Olomouc, Olomouc, Czech Republic.
- Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium.
- Faculty of Medicine, Palacký University Olomouc, Czech Republic.
- Department of Pulmonary Diseases and Tuberculosis, University Hospital Olomouc, Olomouc, Czech Republic.
- Clinical Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium.
ORCID-Profile: Sofie Breuls
Förderung
- Galápagos
- Boehringer Ingelheim
- AstraZeneca Czech Republic
- Fonds Wetenschappelijk Onderzoek
- Roche
Zitieren
APA
Breuls, S., Zlamalova, T., Raisova, K., Blondeel, A., Wuyts, M., Dvoracek, M., Zurkova, M., Yserbyt, J., Janssens, W., Wuyts, W., Troosters, T., & Demeyer, H. (2024). Physical activity coaching in patients with interstitial lung diseases: A randomized controlled trial. Chronic Respiratory Disease, 21. https://doi.org/10.1177/14799731241235231
Vancouver
Breuls S, Zlamalova T, Raisova K, Blondeel A, Wuyts M, Dvoracek M, et al. Physical activity coaching in patients with interstitial lung diseases: A randomized controlled trial. Chronic Respiratory Disease. 2024;21. doi:10.1177/14799731241235231
BibTeX
@article{Breuls2024,
author = {Breuls, Sofie and Zlamalova, Tamara and Raisova, Katerina and Blondeel, Astrid and Wuyts, Marieke and Dvoracek, Martin and Zurkova, Monika and Yserbyt, Jonas and Janssens, Wim and Wuyts, Wim and Troosters, Thierry and Demeyer, Heleen},
title = {Physical activity coaching in patients with interstitial lung diseases: A randomized controlled trial},
journal = {Chronic Respiratory Disease},
year = {2024},
volume = {21},
doi = {10.1177/14799731241235231}
}
EUVIMED